GlassScriptPhysician profile
Michael R Novak
NPI 1972501179
$1,704.81
in general payments reported to CMS, 2019-2025
20 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $34.81 · 2021: $53.06 · 2022: $39.94 · 2023: $171 · 2024: $277 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $343.40 | 2025 | |
| Medtronic USA, INC. | $225.10 | 2019 | |
| Abbott Laboratories | $174.14 | 2025 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $173.87 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.10 | 2024 | Jardiance |
| Novo Nordisk INC | $133.03 | 2025 | Ozempic |
| Osiris Therapeutics INC. | $121.13 | 2019 | |
| Astellas Pharma US INC | $61.48 | 2024 | Izervay |
| Pfizer INC. | $52.49 | 2020-2024 | |
| Lilly USA, LLC | $45.20 | 2021-2024 | Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $42.53 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $33.26 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $29.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.26 | 2022 | |
| Qol Medical, LLC | $22.13 | 2025 | Sucraid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.46 | 2025 | Shingrix |
| Abbvie INC. | $18.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.97 | 2025 | Entyvio |
| Davol INC. | $16.68 | 2022 | |
| Exact Sciences Corporation | $14.05 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.